Latest Annual General Meeting News

Race Oncology Limited has secured shareholder approval for a replacement Constitution at its 2025 Annual General Meeting, updating its corporate governance framework to align with current regulatory standards.

Wesfarmers Limited announces a fully franked special dividend of AUD 0.40 per share alongside a $1.10 capital return, both payable on December 4, 2025. Eligible shareholders can participate in the Dividend Investment Plan for the dividend component, marking a significant move in the company’s 2025 capital management strategy.

Elanor Investors Group has extended deadlines for a $125 million investment from Rockworth Capital Partners and the acquisition of Firmus, with a key shareholder meeting now scheduled for late January 2026.

Verbrec Limited reported record FY2025 financial results with its highest gross and adjusted EBITDA margins in years, alongside strategic moves including the acquisition of Alliance Automation and divestment of its Competency Training business.

Northern Minerals has applied to defer its 2025 AGM as it awaits regulatory review over potential foreign investment breaches, underscoring heightened scrutiny on shareholder compliance.

Elevra Lithium reports a 31% surge in spodumene concentrate production for FY25, alongside significant resource expansions and a clear growth roadmap post-merger.

Lifestyle Communities Limited reported a challenging FY25 marked by a significant $135.5 million after-tax write-down following a VCAT ruling, while signaling early signs of recovery and strategic reset for FY26.

The Star Entertainment Group has secured crucial regulatory approvals to convert a $300 million strategic investment by Bally’s Corporation and Investment Holdings into equity, setting the stage for board changes and a path toward financial recovery.

Reece Limited reported a modest revenue decline and earnings pressure in FY25 amid challenging markets but reinforced its long-term growth strategy with a significant share buyback and board renewal. Early FY26 trading shows sales growth driven by network expansion despite ongoing cost pressures.

Alterity Therapeutics announces significant board changes, including the retirement of founding chairman Geoffrey Kempler and appointment of CEO Dr David Stamler as Managing Director, aligning leadership with its Phase 3 clinical ambitions.

Accent Group Limited reported modest FY25 sales growth with a cautious FY26 outlook, unveiling a strategic partnership to expand Sports Direct stores in Australia and New Zealand.

QuickFee Limited has announced a shareholder-approved return of capital totaling approximately A$28.5 million, funded by proceeds from the sale of its US Pay Now and Connect businesses. Shareholders will receive 7.5 cents per share, with payments scheduled for early December.